Neurological examination
Dinesh Ganapathy, Jasmohan S. Bajaj – 28 June 2016
Clinical examination: Eyes
Andrea A. Tooley, Seth Sweetser – 28 June 2016
Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity
Jannick Prentoe, Rodrigo Velázquez‐Moctezuma, Steven K.H. Foung, Mansun Law, Jens Bukh – 28 June 2016 – There are 3‐4 million new hepatitis C virus (HCV) infections yearly. The extensive intergenotypic sequence diversity of envelope proteins E1 and E2 of HCV and shielding of important epitopes by hypervariable region 1 (HVR1) of E2 are believed to be major hindrances to developing universally protective HCV vaccines.
Examination of the abdomen
Adrian Reuben – 28 June 2016
Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection
Armand Abergel, Sophie Metivier, Didier Samuel, Deyuan Jiang, Kathryn Kersey, Phillip S. Pang, Evguenia Svarovskaia, Steven J. Knox, Veronique Loustaud‐Ratti, Tarik Asselah – 28 June 2016 – Genotype 4 hepatitis C virus (HCV) was considered difficult to treat in the era of pegylated interferon‐alpha (Peg‐IFN‐α) and ribavirin regimens. We evaluated the efficacy and safety of therapy with the nonstructural (NS) 5A inhibitor, ledipasvir, combined with the NS5B polymerase inhibitor, sofosbuvir, in patients with HCV genotype 4.
The gap between clinically assessed physical performance and objective physical activity in liver transplant candidates
Michael A. Dunn, Deborah A. Josbeno, Amy R. Schmotzer, Amit D. Tevar, Andrea F. DiMartini, Douglas P. Landsittel, Anthony Delitto – 27 June 2016 – Frailty with sarcopenia in cirrhosis causes liver transplant wait‐list attrition and deaths. Regular physical activity is needed to protect patients with cirrhosis from frailty. We subjectively assess physical performance in selecting patients for transplant listing, but we do not know whether clinical assessments reflect the extent of activity patients actually perform.
Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)
Nathalie Ganne‐Carrié, Richard Layese, Valérie Bourcier, Carole Cagnot, Patrick Marcellin, Dominique Guyader, Stanislas Pol, Dominique Larrey, Victor Lédinghen, Denis Ouzan, Fabien Zoulim, Dominique Roulot, Albert Tran, Jean‐Pierre Bronowicki, Jean‐Pierre Zarski, Ghassan Riachi, Paul Calès, Jean‐Marie Péron, Laurent Alric, Marc Bourlière, Philippe Mathurin, Jean‐Frédéric Blanc, Armand Abergel, Lawrence Serfaty, Ariane Mallat, Jean‐Didier Grangé, Pierre Attali, Yannick Bacq, Claire Wartelle, Thông Dao, Yves Benhamou, Christophe Pilette, Christine Silvain, Christos Christidis, Dominique Capro
Pure 3‐dimensional laparoscopic extended right hepatectomy in a living donor
Kyung‐Suk Suh, Suk Kyun Hong, Nam‐Joon Yi, Kwang‐Woong Lee, Hyo‐Sin Kim, Kyung Chul Yoon, Hyeyoung Kim – 27 June 2016
High von Willebrand factor antigen levels and procoagulant imbalance may be involved in both increasing severity of cirrhosis and portal vein thrombosis
Georgios N. Kalambokis, Aikaterini Oikonomou, Leonidas Christou, Gerasimos Baltayiannis – 27 June 2016
Lower rates of receiving model for end‐stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma
Kellie Young, Maria Aguilar, Robert Gish, Zobair Younossi, Sammy Saab, Taft Bhuket, Benny Liu, Aijaz Ahmed, Robert J. Wong – 27 June 2016 – Receiving Model for End‐Stage Liver Disease (MELD) exception status for hepatocellular carcinoma (HCC) improves wait‐list survival and probability of liver transplantation (LT). We aim to evaluate etiology‐specific disparities in MELD exception, LT wait‐list times, and post‐LT outcomes among patients with HCC listed for LT.